- Trials with a EudraCT protocol (734)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (7)
734 result(s) found for: Titer.
Displaying page 1 of 37.
EudraCT Number: 2007-002063-27 | Sponsor Protocol Number: V78P5S | Start Date*: 2007-06-28 |
Sponsor Name:Novartis Vaccines and Diagnostics Limited | ||
Full Title: A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of FLUVIRIN® Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2007-2008, when Adm... | ||
Medical condition: Prophylaxis of Influenza | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000787-88 | Sponsor Protocol Number: V78P4S | Start Date*: 2006-06-30 |
Sponsor Name:Chiron Vaccines Limited | ||
Full Title: A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of FLUVIRIN® Surface Antigen, Inactivated Influenza Vaccine, Formulation 2006-2007, when Administered... | ||
Medical condition: Prophylaxis of influenza | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-001300-37 | Sponsor Protocol Number: S201.3.125 | Start Date*: 2006-07-11 |
Sponsor Name:Solvay Pharmaceuticals B.V. | ||
Full Title: Immunogenicity and reactogenicity of the trivalent influenza subunit vaccine Influvac® for the season 2006/2007. An open, baseline-controlled study in two groups of healthy subjects: adult subjects... | ||
Medical condition: Prophylaxis of influenza, especially in those who run an increased risk of associated complications. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-000659-14 | Sponsor Protocol Number: V78P3S | Start Date*: 2005-05-09 |
Sponsor Name:Chiron Vaccines Limited | ||
Full Title: A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of FLUVIRIN® Surface Antigen, Inactivated Influenza Vaccine, Formulation 2005-2006, when administered... | ||
Medical condition: Prophylaxis of influenza | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-014492-46 | Sponsor Protocol Number: B1971016(6108A1-2004) | Start Date*: 2011-05-19 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED, TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BIVALENT rLP2086 VACCINE WHEN ADMINISTERED AS A 3-DOSE REGIMEN IN HEALTH... | |||||||||||||
Medical condition: Pfizer‘s investigational bivalent rLP2086 vaccine is being developed for prevention of invasive meningococcal disease caused by N meningitidis serogroup B. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) PL (Completed) DK (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011004-33 | Sponsor Protocol Number: V78_07S | Start Date*: 2009-06-09 |
Sponsor Name:Novartis Vaccines and Diagnostics GmbH & Co. KG | ||
Full Title: A Phase II, single center, uncontrolled, open label study to evaluate safety and immunogenicity of FLUVIRIN® [Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur], Formulation 2009/2010, when A... | ||
Medical condition: Prophylaxis of influenza | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-023873-20 | Sponsor Protocol Number: B1971009(6108A1-3001) | Start Date*: 2011-11-08 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED TRIAL TO ASSESS THE LOT CONSISTENCY, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MENINGOCOCCAL SEROGROUP B BIVALENT RLP2086 VACCINE IN H... | |||||||||||||
Medical condition: BACTERIAL MENINGITIS. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) FI (Completed) CZ (Completed) GB (Completed) ES (Completed) PL (Completed) IT (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001223-14 | Sponsor Protocol Number: VAJ00001 | Start Date*: 2020-11-13 | |||||||||||
Sponsor Name:Sanofi Pasteur SA | |||||||||||||
Full Title: Imovax® Rabies and VERORAB® Immunogenicity and Safety after One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Intradermal or Intramuscu... | |||||||||||||
Medical condition: Rabies disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005629-38 | Sponsor Protocol Number: Td551 | Start Date*: 2016-01-13 | |||||||||||||||||||||
Sponsor Name:Sanofi Pasteur Inc. | |||||||||||||||||||||||
Full Title: Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents | |||||||||||||||||||||||
Medical condition: Active immunization against tetanus, diphtheria and pertussis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-000875-40 | Sponsor Protocol Number: S201.3.126 | Start Date*: 2007-05-25 | |||||||||||
Sponsor Name:Solvay Pharmaceuticals B.V. | |||||||||||||
Full Title: Immunogenicity and reactogenicity of the trivalent influenza subunit vaccine Influvac® for the season 2007/2008. An open, baseline-controlled multi-centre study in two groups of healthy subjects: ... | |||||||||||||
Medical condition: Prophylaxis of influenza. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018991-25 | Sponsor Protocol Number: GPF18 | Start Date*: 2010-03-15 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Immunogenicity of the Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine Without Adjuvant in Healthy Adult Subjects | ||
Medical condition: Preventive vaccination in healthy subjects aged 18 to 60 years against infection with S-OIV (Swine Origin Influenza Virus) A/California/7/2009 (H1N1) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000477-29 | Sponsor Protocol Number: GPA02 | Start Date*: 2006-05-11 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Safety and immunogenicity of an intramuscular, inactivated, split-virion, pandemic influenza A/H5N1 vaccine in adults and the elderly. | ||
Medical condition: Vaccination of adults (18-60 years) and elderly (>60 years) with pandemic flu H5N1 vaccine. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-000341-11 | Sponsor Protocol Number: S206.3.010 | Start Date*: 2005-06-06 |
Sponsor Name:Solvay Pharmaceuticqals B.V. | ||
Full Title: Immunogenicity and reactogenicity of the trivalent virosomal influenza vaccine Invivac® for the season 2005/2006. An open, baseline controlled study in two groups of healthy subjects: adult subject... | ||
Medical condition: Prophylaxis of influenza in adults and the elderly, especially in those who run an increased risk of associated complications. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-003791-38 | Sponsor Protocol Number: S206.3.011 | Start Date*: 2008-08-23 |
Sponsor Name:Solvay Pharmaceuticals B.V. | ||
Full Title: Immunogenicity and reactogenicity of the trivalent virosomal influenza vaccine Invivac® for the season 2005/2006. An open, baseline controlled study in two groups of healthy subjects: adult subject... | ||
Medical condition: Prophylaxis of influenza in adults and the elderly, especially in those who run an increased risk of associated complications. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-001301-28 | Sponsor Protocol Number: S206.3.012 | Start Date*: 2006-05-19 |
Sponsor Name:Solvay Pharmaceuticals B.V. | ||
Full Title: Immunogenicity and reactogenicity of the trivalent virosomal influenza vaccine Invivac® for the season 2006/2007. An open, baseline-controlled study in two groups of healthy subjects: adult subject... | ||
Medical condition: Prophylaxis of influenza in adults and the elderly, especially in those who run an increased risk of associated complications. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001995-71 | Sponsor Protocol Number: PLATIG-1404 | Start Date*: 2014-07-03 |
Sponsor Name:Plazmaferezis Állomás Közhasznú Nonprofit Kft | ||
Full Title: Open label multicenter prospective trial to assess the tetanus titer in subject of regular plasmapharesis | ||
Medical condition: healthy subjects eligible for tetanus booster vaccination | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003370-41 | Sponsor Protocol Number: VAT00002 | Start Date*: 2021-08-23 | |||||||||||
Sponsor Name:Sanofi Pasteur Inc. | |||||||||||||
Full Title: Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines with AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SA... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000752-14 | Sponsor Protocol Number: GRT82 | Start Date*: 2011-04-19 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation (Intramuscular Route) | ||
Medical condition: Vaccination of healthy subjects aged 18 to 60 years (i.e. to the day before the 61st birthday) or 61 years or above (from the day of the 61st birthday) on the day of inclusion with one dose of the ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-001453-74 | Sponsor Protocol Number: Version01.1. | Start Date*: 2012-05-15 |
Sponsor Name:Institute of Specific Prophylaxis and Tropical Medicine | ||
Full Title: Comparison of vaccination routes: subcutaneus versus intramuscular application of FSME-Immun® | ||
Medical condition: TBE vaccine (FSME-Immun®) is registered for intra-muscular application. Due to medical reasons (e.g. anticoagulant therapy, adipositas) intra-muscular application is not always possible. The aim o... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-000943-33 | Sponsor Protocol Number: GRT83 | Start Date*: 2008-04-23 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation (Intramuscular Route) | ||
Medical condition: Vaccination of healthy subjects aged 18 to 60 years (i.e. to the day before the 61st birthday) or 61 years or above (from the day of the 61st birthday) on the day of inclusion with one dose of the ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.